Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: TUMOR NECROSIS FACTOR-ALPHA - ANTAGONISTS AND INHIBITORS, . Treffer: 28

2011

Brunasso, AM; Massone, C Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab.
Acta Derm Venereol. 2011; 91(1):70-71 Doi: 10.2340/00015555-0989 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Brunasso, AM; Puntoni, M; Gulia, A; Massone, C Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review.
Rheumatology (Oxford). 2011; 50(9):1700-1711 Doi: 10.1093/rheumatology/ker190 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Weger, W An update on the diagnosis and management of psoriatic arthritis.
G Ital Dermatol Venereol. 2011; 146(1): 1-8.
Web of Science PubMed

 

2010

Brunasso, AM; Massone, C Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa.
Eur J Dermatol. 2010; 20(5):644-646 Doi: 10.1684/ejd.2010.1037 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Dejaco, C; Duftner, C; Klotz, W; Schirmer, M; Herold, M Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.
Rheumatol Int. 2010; 30(4):451-454 Doi: 10.1007/s00296-009-0978-4
Web of Science PubMed FullText FullText_MUG

 

El Shabrawi-Caelen, L; La Placa, M; Vincenzi, C; Haidn, T; Muellegger, R; Tosti, A Adalimumab-induced psoriasis of the scalp with diffuse alopecia: A severe potentially irreversible cutaneous side effect of TNF-alpha blockers.
Inflamm Bowel Dis. 2010; 16(2):182-183 Doi: 10.1002/ibd.20954 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

2009

Dejaco, C; Duftner, C; Klotz, W; Schirmer, M; Herold, M Antibodies against mutated citrullinated vimentin fail to predict anti-TNF treatment response in rheumatoid arthritis
SCAND J RHEUMATOL. 2009; 38(1): 66-67. Doi: 10.1080/03009740802220067
Web of Science PubMed FullText FullText_MUG

 

Dejaco, C; Duftner, C; Wipfler, E; Schirmer, M A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation
Wien Med Wochenschr. 2009; 159(3-4): 70-75. Doi: 10.1007/s10354-008-0590-3
PubMed FullText FullText_MUG

 

Emery, P; Van Vollenhoven, R; Ostergaard, M; Choy, E; Combe, B; Graninger, W; Krueger, K; Matucci-Cerinic, M; Navarro, F; van Riel, P; Settas, L; Steinfeld, S Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.
ANN RHEUM DIS. 2009; 68(4): 456-459. Doi: 10.1136/ard.2008.100362 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Fleischmann, R; Vencovsky, J; van Vollenhoven, R; Borenstein, D; Box, J; Coteur, G; Goel, N; Brezinschek, HP; Innes, A; Strand, V Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
Ann Rheum Dis. 2009; 68(6): 805-811. Doi: 10.1136/ard.2008.099291 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2008

Hermann, J; Kovacs, G; Scheidl, S Interdisciplinary point of contact between rheumatology and pneumology
Z RHEUMATOL. 2008; 67(5): 412- 414. Doi: 10.1007/s00393-008-0346-x
Web of Science PubMed FullText FullText_MUG

 

Stojanov, S; Dejaco, C; Lohse, P; Huss, K; Duftner, C; Belohradsky, BH; Herold, M; Schirmer, M Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment.
Ann Rheum Dis. 2008; 67(9): 1292-1298. Doi: 10.1136/ard.2007.079376 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2007

Aringer, M; Steiner, G; Graninger, WB; Höfler, E; Steiner, CW; Smolen, JS Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
Arthritis Rheum. 2007; 56(1): 274-279. Doi: 10.1002/art.22327 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Geier, A; Dietrich, CG; Trauner, M; Gartung, C Extrahepatic cholestasis downregulates Oatp1 by TNF-alpha signalling without affecting Oatp2 and Oatp4 expression and sodium-independent bile salt uptake in rat liver.
Liver Int. 2007; 27(8):1056-1065 Doi: 10.1111/j.1478-3231.2007.01523.x
Web of Science PubMed FullText FullText_MUG

 

Hermann, J; Müller, T; Yazdani-Biuki, B; Aringer, M; Herold, M; Ebner, W; Ofner, P; Graninger, W High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers.
ANN RHEUM DIS. 2007; 66(4): 561-562. Doi: 10.1136/ard.2006.060061 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Thonhofer, R; Uitz, E; Graninger, W Schnitzler's syndrome--exacerbation after anti-TNF treatment.
RHEUMATOLOGY. 2007; 46(6): 1041-1042. Doi: 10.1093/rheumatology/kem048 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Wegscheider, BJ; El-Shabrawi, L; Weger, M; Ardjomand, N; Hermann, J; Aberer, E; El-Shabrawi, Y Adverse skin reactions to infliximab in the treatment of intraocular inflammation.
Eye. 2007; 21(4): 547-549. Doi: 10.1038/sj.eye.6702262 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2006

Duftner, C; Dejaco, C; Kullich, W; Klauser, A; Goldberger, C; Falkenbach, A; Schirmer, M Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis.
Ann Rheum Dis. 2006; 65(5): 647-653. Doi: 10.1136/ard.2005.042085 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hermann, J; Reittner, P; Scarpatetti, M; Graninger, W Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab.
ANN RHEUM DIS. 2006; 65(5): 691-692. Doi: 10.1136/ard.2005.043885 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2005

Deutschmann, A; Mache, CJ; Bodo, K; Zebedin, D; Ring, E Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage.
PEDIATRICS. 2005; 116(5): 1231-1233. Doi: 10.1542/peds.2004-2206 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

El-Shabrawi, Y; Hermann, J Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis.
EYE. 2005; 19(9): 1017-1018. Doi: 10.1038/sj.eye.6701712 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2004

Aringer, M; Graninger, WB; Steiner, G; Smolen, JS Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Arthritis Rheum. 2004; 50(10):3161-3169 Doi: 10.1002/art.20576 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2003

Tilg, H; Jalan, R; Kaser, A; Davies, NA; Offner, FA; Hodges, SJ; Ludwiczek, O; Shawcross, D; Zoller, H; Alisa, A; Mookerjee, RP; Graziadei, I; Datz, C; Trauner, M; Schuppan, D; Obrist, P; Vogel, W; Williams, R Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis.
J Hepatol. 2003; 38(4):419-425 Doi: 10.1016/S0168-8278(02)00442-7
Web of Science PubMed FullText FullText_MUG

 

2002

Aringer, M; Graninger, WB Treating rheumatoid arthritis with new disease modifying drugs.
Acta Med Austriaca. 2002; 29(1):33-35 Doi: 10.1046/j.1563-2571.2002.01042.x
Web of Science PubMed FullText FullText_MUG Google Scholar

 

El-Shabrawi, Y; Hermann, J Case series of selective anti-tumor necrosis factor alpha therapy using infliximab in patients with nonresponsive chronic HLA-B27-associated anterior uveitis: comment on the articles by Brandt et al.
Arthritis Rheum. 2002; 46(10):2821-2822 Doi: 10.1002/art.10469 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Graninger, W; Smolen, J Treatment of rheumatoid arthritis by TNF-blocking agents.
Int Arch Allergy Immunol. 2002; 127(1):10-14 Doi: 10.1159/000048164
Web of Science PubMed FullText FullText_MUG

 

2001

Aringer, M; Steiner, G; Graninger, W; Smolen, J Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky.
Arthritis Rheum. 2001; 44(7):1721-1722 Doi: 10.1002/1529-0131(200107)44:7<1721::AID-ART302>3.0.CO;2-J [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Graninger, WB; Smolen, JS One-year inhibition of tumor necrosis factor-alpha: a major success or a larger puzzle?
Curr Opin Rheumatol. 2001; 13(3):209-213 Doi: 10.1097/00002281-200105000-00010
Web of Science PubMed FullText FullText_MUG

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum